Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 317

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 19
Chunk 317
---
a a letter terminating the exclusive license agreement signed on March 31, 2023. Termination has been effective on October 24, 2024.

On September 23, 2024, Innate Pharma announced the U. S Food and Drug Administration (FDA) cleared its investigational new drug (IND) application to initiate a Phase 1 clinical study of IPH4502, its novel and differentiated topoisomerase I inhibitor antibody drug conjugate (ADC) targeting Nectin-4 in solid tumors.

On October 9, 2024, the Company received a letter terminating the license agreement with Sanofi for IPH67. Termination was effective on January 7, 2025. Innate has regained full rights to IPH67, a natural killer cell engager, from ANKET® platform program currently under development in solid tumors. The rest of the 2022 collaboration and license agreement with Sanofi remains unchanged.

On October 14, 2024, the Company announced that its Supervisory Board appointed Jonathan Dickinson as the Company’s new Chief Executive Officer (CEO) and Chairman of the Executive Board, effective November 1, 2024. Jonathan Dickinson succeeded Hervé Brailly, interim CEO

During the third quarter of 2024, Innate received an initial notice from the FDA supporting its regulatory plans for lacutamab, including a Fast Track designation for the treatment of patients with relapsed or refractory Sézary syndrome, and the Company is pursuing discussions with the FDA regarding a confirmatory Phase 3 trial.

On December 6, 2024, the Company announced an agreement to clinically study the potential of IPH6501, Innate's anti-CD20 ANKET® in follicular lymphoma (FL) with The Institute for Follicular Lymphoma Innovation (IFLI). To support the Phase 1/2 trial and inclusion of FL patients, IFLI will initially invest 3 1.56 2.26 4.9

On December 10, the Company signed an agreement with Natixis for the assignment of research tax credit receivable relating to 2023 expenditure, without recourse discounting. The Company received 8.6

On November 13, 2024, the Executive Board granted 370,560 1,162,900 750,000

On December 31, 2024, the Executive Board approved the final performance as of December 31, 202